<![CDATA[IndiTreat® to be distributed in Czech Republic and Slovakia]]>IndiTreat® to be distributed in Czech Republic and Slovakia through Promedica
2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announced today that Promedica Prague Group, the largest independent healthcare distributor in the Czech Republic, will bring IndiTreat® products to Czech and Slovakian patients and professionals. This new collaboration agreement brings the total of 2cureX partners to 9, covering 14 European countries and a combined population of 235 million people.
2cureX and Promedica Prague Group have signed an agreement by which Promedica Prague Group becomes the distributor of IndiTreat® products in Czech Republic and Slovakia. Under the terms of the collaboration, Promedica Prague Group will promote IndiTreat® to oncology professionals, sign supply agreements with hospitals and manage the sample logistics between the hospitals and 2cureX labs in Copenhagen.

IndiTreat® present in 14 countries

]]>https://dev.proinvestor.com/forum/topic/443528/inditreat-to-be-distributed-in-czech-republic-and-slovakiaRSS for NodeThu, 02 Jul 2026 21:23:43 GMTTue, 11 Jan 2022 07:46:17 GMT60<![CDATA[Reply to IndiTreat® to be distributed in Czech Republic and Slovakia on Tue, 11 Jan 2022 09:31:15 GMT]]>Analyse fra Mangold... https://www.2curex.com/wp-content/uploads/2cureX_update_2021-10-29.pdf

]]>https://dev.proinvestor.com/forum/post/9472791https://dev.proinvestor.com/forum/post/9472791Tue, 11 Jan 2022 09:31:15 GMT<![CDATA[Reply to IndiTreat® to be distributed in Czech Republic and Slovakia on Tue, 11 Jan 2022 08:30:05 GMT]]>De begynder virkelig at få foden indenfor i mange lande efterhånden....utrolig spændende firma, med styr på omkostningerne.

]]>https://dev.proinvestor.com/forum/post/9472786https://dev.proinvestor.com/forum/post/9472786Tue, 11 Jan 2022 08:30:05 GMT